Benign Prostatic Hyperplasia. Enlarged prostate without lower urinary tract symptoms
Conditions
Interventions
Intervention 1: Patients with serum vitamin D levels receive tamsulosin tablets (Farabi Company) at a dose of 0.4 mg daily and silymarin capsules 240 mg (manufactured by Rose Pharmed Biotechnology Com
Sponsors
Islamic Azad University
Eligibility
Sex/Gender
Male
Age
50 Years to No maximum
Inclusion criteria
Inclusion criteria: PSA 8
Exclusion criteria
Exclusion criteria: - kidney failure - Urine retention - Prostate cancer - Liver disease - Active infection - Malignancy - Stone in urethra ,bladder , ureters - Prostate inflammation - Hematuria - History of cystoscopy - History of pelvic or urology surgery - Diabetes - Neurological diseases(Parkinson , MS , CVA ,waist disk ) - Heart failure - History of pelvic radiotherapy - History or concomitant use of antidepressant ,antihistamine , bronchodilator ,diuretic , narcotic - History of 5alpha reductase inhibitor and phosphodiesterase inhibitors drugs use - History of tuberculosis - History of urinary tract and perineum trauma - History of permanent consumption of alcohol , caffeine and excessive fluid intake - History of psychological diseases ( schizophrenia , severe depression ) History of waist - History or concomitant use of yohimbine , metronidazole , anticholinergic drugs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improve quality of life{Description of outcome variable: prostate volume (measurement intervals at the beginning of the study / three months later). Timepoint: 1 month and 3 month. Method of measurement: How to measure the variable: ultrasound}.;Changes in the severity of symptoms. Timepoint: Begin, 1 m, 3m. Method of measurement: IPSS.;PSA change. Timepoint: Begin, 3m. Method of measurement: serology. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr.Mehdi Rajabi
Islamic Azad University
Outcome results
None listed